
NEXT-GENERATION TECHNOLOGY
Delivers like nothing else.
Boston Scientific's Ranger Drug-Coated Balloon is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform1 with the lowest tip entry profile of any SFA DCB2. For ease, durability and effectiveness, Ranger DCB delivers like nothing else.

BOLD CLINICAL TRIALS
Two Randomized Controlled DCB Trials.
Zero doubt.
Bold is being the first company to voluntarily evaluate our Drug-Coated Balloon against another DCB in a Level-1 Randomized Controlled Trial for comparative effectiveness. Ranger™ DCB demonstrated similar primary patency as IN.PACT with half the total drug dose3 at 2-Years. And consistently demonstrated high primary patency, near 90%, at 1-Year in the RANGER II SFA & COMPARE Trials4.
Clinical Highlights
Exceptional outcomes at 2-Years. No matter the lesion complexity. No matter the patient.5
In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency
at 2-Years.5
2.Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
3. COMPARE Clinical Trial 2-Year Results presented by Sabine Steiner, MD. LINC 2021. Based on total drug dose for (4mmx60mm) or (average for full size matrix) per Ranger™ Paclitaxel-Coated PTA Balloon Catheter and IN.PACT™ Admiral Instructions for Use.
4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.
5. RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD. VIVA 2021.

RESTENOSIS REPLACEMENT PROGRAM
Standing together.
The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis.

Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
